ars-pharma.com (SPRY): Net earnings per share growth forecast for next year
The growth foundation of ARS Pharmaceuticals (SPRY) is based on high-margin, patented needle-free epinephrine. The history of earnings per share (EPS) expectation changes on the general GURU.Markets platform chart confirms this potential, where the current figure is 59.50. Development relies on the uniqueness of the Neffy spray in emergency medicine and the professionalism of CEO Richard Leventhal, who ensured a precise product launch.
SPRY (ars-pharma.com): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- company book value details:
- company total debt and liquidity indicators:
Debt to Equity ARS Pharmaceuticals|SPRY - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ARS Pharmaceuticals, Inc.|SPRY - Aggregate Debt Obligations|Debt to Book Capitalization Ratio ARS Pharmaceuticals|SPRY - Long-Term Liabilities|Company Short-Term Debts ARS Pharmaceuticals|Quick Ratio ars-pharma.com
- earnings and valuation multiples information:
SPRY - Net Profit|Expected Profit ARS Pharmaceuticals|SPRY - Company Value to Net Income|Future Price to Earnings ARS Pharmaceuticals|SPRY - Price/Earnings to Growth Multiple|EV/EBITDA Multiple ARS Pharmaceuticals|SPRY - Operating profit EBITDA|Net earnings per share (EPS TTM) ARS Pharmaceuticals|SPRY - Net earnings per share for the last 12 months|Quarterly EPS earnings growth ars-pharma.com|SPRY - Earnings per share growth rate in current year|Expected earnings per share growth for next year ARS Pharmaceuticals
Fundamental company valuation:SPRY, ARS Pharma
This indicator measures the expected change in earnings per share, reflecting the sensitivity of future cash flows to the cost of capital and market expectations. In the context of the expansion of the revolutionary nasal spray from ARS Pharmaceuticals (SPRY), the projected n+1 earnings per share dynamics visualize the company's transition from the investment stage to a phase of explosive product commercialization.
Who ARS Pharmaceuticals competes with
HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year LGND (Ligand)|Earnings growth forecast for next year Amneal Pharmaceuticals, Inc. AMRX|PRGO - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ALVO (Alvotech Biopharmaceuticals)|Liquidia Corporation (LQDA) - Net earnings per share growth forecast for next year|GLPG - Consensus forecast of earnings per share growth for next year|Expected earnings per share growth for next year ANIP|MNKD: Expected earnings per share trend next year|Net earnings per share growth forecast for next year Amphastar (AMPH)|PCRX: Net earnings per share change forecast for next year|Earnings growth forecast for next year TBPH (Theravance Biopharma)|Expected earnings per share trend next year AQST|scPharma - Earnings growth forecast for next year|TECX - Earnings growth forecast for next year|Tonix Pharmaceuticals Inc. (TNXP) - Net earnings per share growth forecast for next year|China SXT Pharmaceuticals, Inc. - Expected earnings per share trend next year|Net earnings per share growth forecast for next year Eupraxia Pharmaceuticals, Inc.|Expected earnings per share growth for next year bioharvest.com (BHST)|Earnings growth forecast for next year EXOZ|Earnings growth forecast for next year oramed.com (ORMP)|Earnings growth forecast for next year ENTX (Entera Bio)|HYFT - Expected earnings per share growth for next year|ABVC BioPharma - Earnings growth forecast for next year|Expected net earnings per share growth next year cumberlandpharma.com|QNTM (Quantum BioPharma) - Expected earnings per share growth for next year|FibroGen Inc (FGEN) - Earnings growth forecast for next year|Expected earnings per share growth for next year TELO|RANI (Rani Therapeutics Inc) - Projected earnings per share increase next year|Earnings growth forecast for next year SNYR|Consensus forecast of earnings per share growth for next year rallybio.com|Earnings growth forecast for next year LEXX (Lexaria Bioscience Corp.)|PULM - Expected earnings per share growth for next year|Pheton - Earnings growth forecast for next year|APM - Earnings growth forecast for next year|Lyra Therapeutics, Inc. (LYRA) - Net earnings per share growth forecast for next year|IBO (Impact BioMedical, Inc.) - Net earnings per share growth forecast for next year|Net earnings per share growth forecast for next year TNF Pharmaceuticals Inc.|cbdMD Corp (YCBD) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year PainReform Limited (PRFX)|Consensus forecast of earnings per share growth for next year altamiratherapeutics.com|Net earnings per share growth forecast for next year Lipella Pharmaceuticals LIPO|OPTN (optinose.com) - Net earnings per share change forecast for next year|PIRS - Net earnings per share growth forecast for next year|Expected earnings per share trend next year PROC (Procaps Group)|PTPI (Petros) - Expected earnings per share growth for next year|Expected net earnings per share growth next year Qilian International Corp (QLI)|Net earnings per share growth forecast for next year Acelyrin, Inc.|tffpharma.com - Net earnings per share change forecast for next year
